Here are the 424B prospectus supplements from Vera Therapeutics, Inc. (VERA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERA filings page.
Vera Therapeutics is offering $200,000,000 of its Class A common stock in a primary public offering, and has granted underwriters an option to buy up to an additional $30,000,000 of shares. The company plans to use the cash, together with existing funds and its Oxford loan facility, to fund the potential commercial launch of its lead drug atacicept for IgA nephropathy, expand atacicept into new clinical indications, and support general corporate purposes such as working capital and capital spending.
Vera is a late clinical-stage biotechnology company focused on serious immunological diseases. Atacicept has shown positive Phase 2b results in IgA nephropathy, a pivotal Phase 3 trial has completed enrollment, and a Biologics License Application was submitted to the FDA through the Accelerated Approval Program on November 7, 2025. Management believes proceeds from this deal, combined with existing resources, will be sufficient to fund projected operating requirements through a potential 2026 U.S. launch of atacicept in IgA nephropathy, if approved, but investors face immediate dilution, no expected dividends, and risks around market liquidity and broad management discretion over how proceeds are spent.